Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Disease
NCT ID: NCT06688981
Last Updated: 2024-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
100 participants
OBSERVATIONAL
2024-10-12
2034-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. AI-based fully automatic segmentation techniques for the accurate identification of kidneys, liver, and cysts, with a focus on AI interpretability and robustness;
2. advanced AI-based image processing techniques allowing to identify new imaging biomarkers, including through the use of radiomics, to characterize ADPKD tissue microstructure and therefore stage the disease and monitor and predict disease progression and response to therapy;
3. multiparametric models including image-based radiomic features alongside clinical and laboratory data to stratify ADPKD patients and predict ADPKD progression over time.
The study will also have the secondary aim of validating the novel techniques against gold standard (manual) methods, when available.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Artificial Intelligence-based Techniques to Characterize KIdney Microstructure on Histological ImagEs
NCT06690190
Early PKD Observational Cohort Study
NCT02936791
Renal Cancer Detection Using Convolutional Neural Networks
NCT03857373
Kidney AI-enabled Care Transformation
NCT05056909
Artificial Intelligence System for the Detection and Prediction of Kidney Diseases Using Ocular Information
NCT05223712
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Total kidney, liver, and cyst volume measurements are based on kidney segmentation, which is generally performed by manual contouring, an operator-dependent and time-consuming task requiring dedicated expertise. Automatic or semi-automatic methods for kidney and cysts segmentation have been proposed in the past based on traditional approaches and artificial intelligence (AI) techniques. However, the low explainability and the need of large and curated datasets allowing to obtain accurate and generalized models have so far hampered their wide adoption in clinical research. A fully automatic segmentation method for the accurate identification of kidneys, liver, and cysts would be highly desirable.
Beyond kidney, liver, and cyst volume quantification, the characterization of non-cystic renal tissue may provide additional relevant information on ADPKD pathophysiology. Few years ago, a contrastenhanced CT study revealed the presence of peritubular interstitial fibrosis in the non-cystic component of ADPKD kidneys, that was associated with renal function and its decline over time, confirmed more recently by an independent study on dynamic contrast-enhanced T1-weighted MRI. Advanced image processing techniques, such as radiomics, which aims to compute high throughput information from radiological images for the characterization of tissue spatial heterogeneity, show potential to characterise tissue microstructure. Preliminary attempts on ADPKD patients were performed on T1-weighted and T2-weighted MRI scans. Besides, radiomics could be helpful to build multiparametric stratification and prediction models including image-based features.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients
ADPKD patients
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mario Negri Institute for Pharmacological Research
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giuseppe Remuzzi, M.D.
Role: STUDY_DIRECTOR
Istituto Di Ricerche Farmacologiche Mario Negri
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
Ranica, BG, Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
He X, Hu Z, Dev H, Romano DJ, Sharbatdaran A, Raza SI, Wang SJ, Teichman K, Shih G, Chevalier JM, Shimonov D, Blumenfeld JD, Goel A, Sabuncu MR, Prince MR. Test Retest Reproducibility of Organ Volume Measurements in ADPKD Using 3D Multimodality Deep Learning. Acad Radiol. 2024 Mar;31(3):889-899. doi: 10.1016/j.acra.2023.09.009. Epub 2023 Oct 3.
Kline TL, Edwards ME, Fetzer J, Gregory AV, Anaam D, Metzger AJ, Erickson BJ. Automatic semantic segmentation of kidney cysts in MR images of patients affected by autosomal-dominant polycystic kidney disease. Abdom Radiol (NY). 2021 Mar;46(3):1053-1061. doi: 10.1007/s00261-020-02748-4. Epub 2020 Sep 17.
Kline TL, Korfiatis P, Edwards ME, Bae KT, Yu A, Chapman AB, Mrug M, Grantham JJ, Landsittel D, Bennett WM, King BF, Harris PC, Torres VE, Erickson BJ; CRISP Investigators. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2017 Nov;92(5):1206-1216. doi: 10.1016/j.kint.2017.03.026. Epub 2017 May 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AI4PKD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.